SBIR/STTR Research Award
A Resorbable Hemostat for Laparoscopic Partial Nephrectomy (LPN)
Award amount
$405,211Program and phase
SBIR · Phase IAward year
2012Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- KOAG MEDICAL, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA11-096
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): There is need for an improved, hemostatic dressing to control renal hemorrhage associated with new nephron-sparing endourologic procedures such as laparoscopic partial nephrectomy (LPN). Our surgical laboratory and small business (KOAG) has developed a cost-effective, microfibrillar chitosan hemostat approved by the FDA for topical use. Chitosan is sourced from chitin, earth's second most natural abundant biopolymer and seafood industry waste product. Chitosan is a biodegradable polyglucosamine polymer that requires depyrogenation before implantation in humans. Our goal is to meet the need for a cost-effective endourologic resorbable hemostat by innovative nitrogen plasma detoxification of microfibrillar chitosan. Our Phase I SBIR study is designed to optimize a non-thermal nitrogen plasma depyrogenation method and simultaneously increase mucoadhesivity and hemostatic effectiveness by surface nitrogenation. A safety and efficacy study of the biocompatibility and hemostaticeffectiveness of depyrogenated-nitrogenated microfibrillar chitosan will be conducted in the porcine LPN model as a Phase I study with proof of safety and efficacy. A head-to-head comparison of our product to other available LPN hemostats will be conducted as a Phase II study. PUBLIC HEALTH RELEVANCE: Development of an economical, resorbable hemostat that can be applied endoscopically will facilitate advances in minimal invasive nephron sparing surgery. An innovative detoxification procedure - lowtemperature nitrogen plasma - will be used to detoxify microfibrillar chitosan for implantation.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)